It was evaluated in combination with margetuximab, an anti-HER2 antibody, in patients with platinum-resistant ovarian and cervical cancer; however, preliminary data did not show a confirmed ORR in these tumor types [94]. The gene discussed is ERBB2; the disease is neoplasm.